Bevacizumab and risk of intracranial hemorrhage in patients with brain metastases: a meta-analysis

Administration of bevacizumab to patients with brain metastases (BM) is controversial due to concerns about the increased risk of intracranial hemorrhage (ICH). This meta-analysis assessed whether the risk of ICH increases in BM patients receiving treatments that contain bevacizumab versus without....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Lin, Chen, Chuan-Jie, Guo, Xiao-Ling, Wu, Xiao-Cui, Lv, Bo-Jie, Wang, Hong-Li, Guo, Zhi, Zhao, Xiang-Yang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846997/
https://www.ncbi.nlm.nih.gov/pubmed/29170906
http://dx.doi.org/10.1007/s11060-017-2693-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5846997/
https://www.ncbi.nlm.nih.gov/pubmed/29170906
http://dx.doi.org/10.1007/s11060-017-2693-4

Ejemplares similares